|
|
Post by prcgorman2 on Aug 6, 2019 13:14:55 GMT -5
If a remote coaching provider like OneDrop could be engaged by MNKD to provide some period of training to new Afrezza users (a few months minimum) and actually go beyond the label utilizing developed experience with real world patients to instruct (this latter part is the big 'IF'), that could greatly benefit retention of patients and subsequently retention of newly prescribing docs. Based on what OneDrop charges for coaching per month, it seems 3 to 6 months of coaching might be a very reasonable addition to acquisition costs to boost retention. Only hitch is whether by being paid by MNKD they would then be stuck with adhering to only dosing info on label. Unlike clinics, this would be far less capital intensive and providing the service inexpensive enough that it could likely be absorbed without having to persuade insurers to foot the bill. I suspect it is not possible. Everything you wrote is rational and understandable and I have no disagreement.
With regard to my speculations on BlueHale use of sound to estimate Afrezza dose, Casper06 said he thought I meant to say we need a deal with a CGM maker. I did not mean to say that and I am not sure how the subject of BlueHale estimation of Afrezza dose is related to a deal with a CGM manufacturer, so I was asking Casper06, "What kind of deal (with a CGM manufacturer)?"
|
|
|
|
Post by prcgorman2 on Aug 6, 2019 13:16:23 GMT -5
You may be right. Because the cartridges are 4, 8, and 12U, I assumed 1, 2, and 3x durations of sound of powder moving through the Dreamboat. The signature of sound might show a short duration (less than 1 second) of air without powder, followed by a duration of air mixed with powder, and then a much longer duration of air without powder again assuming most of the inhale is simply air and that the cartridge empties within a second or two. Again, all speculation based on what the Mannkind paper said about how BlueHale uses sound to estimate pressure and rate of flow and assuming air+powder sounds different than air only. But, I don’t really know. Mannkind says that "BluHale® is a wireless pressure sensing technology that mounts onto our dry powder delivery systems." I interpret that to mean that it doesn't sense sound or duration, just the pressure drop as someone inhales. Since that wouldn't vary by cartridge, I doubt that it can determine the actual amount of drug given. The user would have to enter the number somewhere. There is an earlier post where I copy-and-pasted from a Mannkind document that said BlueHale was instrumented with an audio sensor and used sound. |
|
paul
Researcher
Posts: 134
|
Post by paul on Aug 6, 2019 13:59:19 GMT -5
Mannkind says that "BluHale® is a wireless pressure sensing technology that mounts onto our dry powder delivery systems." I interpret that to mean that it doesn't sense sound or duration, just the pressure drop as someone inhales. Since that wouldn't vary by cartridge, I doubt that it can determine the actual amount of drug given. The user would have to enter the number somewhere. There is an earlier post where I copy-and-pasted from a Mannkind document that said BlueHale was instrumented with an audio sensor and used sound. That paper says "Since higher flows (and greater sounds) result from higher pressures, the sensor output was calibrated to applied pressure." In other words, the sound is just used to measure the pressure. Best I can read the document, all it captures are pressure-time profiles.
|
|
|
|
Post by prcgorman2 on Aug 6, 2019 14:50:54 GMT -5
There is an earlier post where I copy-and-pasted from a Mannkind document that said BlueHale was instrumented with an audio sensor and used sound. That paper says "Since higher flows (and greater sounds) result from higher pressures, the sensor output was calibrated to applied pressure." In other words, the sound is just used to measure the pressure. Best I can read the document, all it captures are pressure-time profiles.
Agree. I said repeatedly I was speculating how sound could be used to estimate dosing, and the reason I was speculating about sound was because that's what Mannkind had shared about how BlueHale worked, and the reason I speculated at how sound could be used to estimate dosing is because the PR mentioned BlueHale and "dosing information". |
|
|
|
Post by sportsrancho on Aug 6, 2019 16:15:50 GMT -5
|
|
|
|
Post by goyocafe on Aug 10, 2019 9:23:48 GMT -5
I was left wanting more information after this collaboration was announced. What is the timeframe for this integration to make its debut? If there is a bigger collaboration possible with Google/Verily, could they participate in miniaturizing the BlueHale device (making it suitable for mass production), much like they’ve done with the G7 for Dexcom?
|
|
|
|
Post by agedhippie on Aug 10, 2019 12:13:05 GMT -5
I was left wanting more information after this collaboration was announced. What is the timeframe for this integration to make its debut? If there is a bigger collaboration possible with Google/Verily, could they participate in miniaturizing the BlueHale device (making it suitable for mass production), much like they’ve done with the G7 for Dexcom? Come up with $250M and an additional $280M in a milestone payment agreement like Dexcom did and you can be Verily's friend as well. Otherwise... |
|
|
|
Post by ktim on Aug 12, 2019 16:31:05 GMT -5
I was left wanting more information after this collaboration was announced. What is the timeframe for this integration to make its debut? If there is a bigger collaboration possible with Google/Verily, could they participate in miniaturizing the BlueHale device (making it suitable for mass production), much like they’ve done with the G7 for Dexcom? There are many consumer electronics design houses that could assist in productizing BluHale (probably low 6 figure cost), though as long as it is add on device it will always be a bit clunky. And they may not want to significantly increase the cost of dreamboat, as a disposable device, by building it in. |
|
|
|
Post by mnholdem on Aug 12, 2019 16:39:04 GMT -5
There is one aspect of the Collaboration between MannKind and One Drop that could use further clarification. Will the MannKind sales force be selling One Drop when they visit clinics? It will be advantageous to have more than one product in the sales presentation.
|
|
|
|
Post by uflawdog on Sept 17, 2019 1:36:49 GMT -5
|
|
|
|
Post by mnholdem on Sept 17, 2019 4:17:17 GMT -5
Excerpt:
By connecting to One Drop, Afrezza users will be able to take advantage of the platform’s AI-enabled glucose forecasts and one-on-one connections to certified diabetes educators, among other features.
“Earlier this year, One Drop announced clinical data that demonstrated using Afrezza with One Drop provided a significant improvement in A1C levels,” says MannKind CEO Michael Castagna, explaining the partnership. “We believe the future of diabetes management will increasingly depend on data collected on a smartphone that provides real-time decision support insights.”
|
|
|
|
Post by goyocafe on Sept 17, 2019 5:26:39 GMT -5
OneDrop is sold in Apple stores. Will the Bluehale device get similar coverage? |
|
paul
Researcher
Posts: 134
|
Post by paul on Sept 17, 2019 7:25:04 GMT -5
When will it be available?
|
|
|
|
Post by matt on Sept 17, 2019 7:57:09 GMT -5
OneDrop is sold in Apple stores. Will the Bluehale device get similar coverage? It depends on how FDA labels the device. Simple medical devices, like thermometers and blood pressure monitors, can be sold anywhere while other devices can be dispensed only on the orders of a physician (i.e. the sale requires a written prescription); that implies a level of regulatory infrastructure Apple stores do not have. Since BluHale is intended to dispense a prescription drug it will probably be available through the same channels as Afrezza itself. |
|
|
|
Post by mnkdfann on Sept 17, 2019 9:00:11 GMT -5
OneDrop is sold in Apple stores. Will the Bluehale device get similar coverage? It depends on how FDA labels the device. Simple medical devices, like thermometers and blood pressure monitors, can be sold anywhere while other devices can be dispensed only on the orders of a physician (i.e. the sale requires a written prescription); that implies a level of regulatory infrastructure Apple stores do not have. Since BluHale is intended to dispense a prescription drug it will probably be available through the same channels as Afrezza itself. For the sake of discussion, how hard would that be to develop? I know it is not the same thing, but Apple can manage educational orders that require verification. And Apple already has at least one certified prescribing app in its store. Perhaps Apple could not handle walk-in purchases with a prescription, but I'm open to the idea that they may have the infrastructure to be able to handle simple medical devices that are prescribed electronically in advance (through a certified e-prescribe app) without too much trouble. Having said that, I think your last line is the most likely. Besides which, why would Apple even want to bother until sale sales of Afrezza are many many multiples beyond where they are now. |
|
